These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9661172)

  • 1. IGF in the clinic.
    Brower V
    Nat Biotechnol; 1998 Jul; 16(7):601-2. PubMed ID: 9661172
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?].
    Meyer CH; Kroll P; Hammes HP
    Klin Monbl Augenheilkd; 2005 Apr; 222(4):353-4. PubMed ID: 15844050
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cephalon adds to clinical disappointment in 1997.
    Glaser V
    Nat Biotechnol; 1997 Jun; 15(6):495-6. PubMed ID: 9181559
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes treatments near and far.
    Kling J
    Nat Biotechnol; 1996 Apr; 14(4):428. PubMed ID: 9630912
    [No Abstract]   [Full Text] [Related]  

  • 6. [Internet and amyotrophic lateral sclerosis treatment: what is wrong?].
    Meininger V; Antoine JC; Arne-Bes MC; Broussolle E; Bruneteau G; Camdessanche JP; Camu W; Carluer L; Cintas P; Clavelou P; Corcia P; Couratier P; Danel-Brunaud V; Desnuelle C; Destée A; Dib M; Fleury MC; Furby A; Giroud M; Gonzales J; Guy N; Kolev I; Lacomblez L; Lardillier-Noel D; Le Forestier N; Maugin D; Nicolas G; Pittion S; Pouget J; Pradat PF; Rousso E; Salachas F; Soriani MH; Tranchant C; Vandenberghe N; Verschueren A; Viader F; Vial C
    Rev Neurol (Paris); 2009 Mar; 165(3):207-10. PubMed ID: 19217130
    [No Abstract]   [Full Text] [Related]  

  • 7. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 8. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
    Clemmons DR
    Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human insulin-like growth factor I and treatment in diabetes].
    Koivisto VA
    Duodecim; 1994; 110(23-24):2197-201. PubMed ID: 8654239
    [No Abstract]   [Full Text] [Related]  

  • 10. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus.
    Christ ER; Carroll PV; Albany E; Umpleby AM; Lumb PJ; Wierzbicki AS; Sönksen PH; Russell-Jones DL
    Am J Physiol Endocrinol Metab; 2002 May; 282(5):E1154-62. PubMed ID: 11934682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention trials.
    Diabetes Forecast; 2002 Oct; 55(10):64. PubMed ID: 14768589
    [No Abstract]   [Full Text] [Related]  

  • 14. HDAC inhibitors overcome first hurdle.
    Garber K
    Nat Biotechnol; 2007 Jan; 25(1):17-9. PubMed ID: 17211382
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
    Ranke MB
    Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy].
    Peczyńska J; Urban M; Głowińska B; Urban B
    Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
    Moss RW
    New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
    [No Abstract]   [Full Text] [Related]  

  • 19. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 20. [Novo Nordisk introduces a new basic insulin for marketing].
    Krankenpfl J; 2004; 42(5-6):168-9. PubMed ID: 15527230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.